PARP inhibitors for the treatment and prevention of breast cancer

Current Breast Cancer Reports

Volumn 2, Issue 4, 2010, Pages 190-197

  Vinayak, Shaveta ^a   Ford, James M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA; Breast cancer; BSI 201; DNA repair; Hormone receptor negative breast cancer; Olaparib; Poly (ADP Ribose) Polymerase (PARP) inhibitor; Prevention; Triple negative breast cancer

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; CEP 8983; CISPLATIN; DNA; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; INIPARIB; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; RALOXIFENE; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DNA REPAIR; DRUG DOSE ESCALATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HIGH RISK PATIENT; HOMOLOGOUS RECOMBINATION; HUMAN; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 78149470596     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-010-0026-0     Document Type: Review

References (36)

1. Ford JM, Kastan MB: DNA damage response pathways and cancer. In Abeloff's Clinical Oncology. Edited by Abeloff MD. Philadelphia: Churchill Livingstone; 2008:139-152.
2. M Spry T Scott H Pierce JA D'Orazio 2007 DNA repair pathways and hereditary cancer susceptibility syndromes Front Biosci 12 4191 4207 1:CAS:528:DC%2BD2sXms1Kls7c%3D 10.2741/2380 17485367
3. BP Rowe PM Glazer 2010 Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms Breast Cancer Res 12 203 10.1186/bcr2566 20459590
4. NJ Curtin 2005 PARP inhibitors for cancer therapy Expert Rev Mol Med 7 1 20 10.1017/S146239940500904X 15836799 (Pubitemid 43118235)
5. M Rouleau A Patel MJ Hendzel, et al. 2010 PARP inhibition: PARP1 and beyond Nat Rev Cancer 10 293 301 1:CAS:528:DC%2BC3cXis1yms7w%3D 10.1038/nrc2812 20200537
6. BW Durkacz O Omidiji DA Gray S Shall 1980 (ADP-ribose) participates in DNA excision repair Nature 283 593 596 1:CAS:528:DyaL3cXktVagtLc%3D 10.1038/283593a0 6243744
7. A Simons N Dafni I Dotan, et al. 2001 Establishment of a chemical synthetic lethality screen in cultured human cells Genome Res 11 266 273 1:CAS:528:DC%2BD3MXht1GqtLk%3D 10.1101/gr.154201 11157789 (Pubitemid 32166535)
8. H Bryant N Schultz H Thomas, et al. 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913 917 1:CAS:528:DC%2BD2MXjtFOmsrY%3D 10.1038/nature03443 15829966 (Pubitemid 40559005)
9. H Farmer N McCabe CJ Lord, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917 921 1:CAS:528:DC%2BD2MXjtFOmsrc%3D 10.1038/nature03445 15829967 (Pubitemid 40559006)
10. AR Hartman JM Ford 2002 BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair Nat Genet 32 180 184 1:CAS:528: DC%2BD38Xms1ajsLg%3D 10.1038/ng953 12195423 (Pubitemid 34977215)
11. E Alli VB Sharma P Sunderesakumar JM Ford 2009 Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase Cancer Res 69 3589 3596 1:CAS:528:DC%2BD1MXksV2ht7k%3D 10.1158/0008-5472.CAN-08-4016 19351835
12. S Narod 2002 Modifiers of risk of hereditary breast and ovarian cancer Nat Rev Cancer 2 113 123 10.1038/nrc726 12635174 (Pubitemid 37328798)
13. S Narod W Foulkes 2004 BRCA1 and BRCA2: 1994 and beyond Nat Rev Cancer 4 665 676 1:CAS:528:DC%2BD2cXntFCmsbk%3D 10.1038/nrc1431 15343273 (Pubitemid 39215065)
14. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
15. T Sorlie R Tibshirani J Parker, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 8418 8423 1:CAS:528:DC%2BD3sXlsFGntLk%3D 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
16. S Cleator W Heller RC Coombes 2007 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235 244 10.1016/S1470-2045(07)70074-8 17329194 (Pubitemid 46291713)
17. BP Schneider EP Winer WD Foulkes, et al. 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 8010 8018 1:CAS:528:DC%2BD1cXhsV2it73F 10.1158/1078-0432.CCR-08-1208 19088017
18. Hastak K, Alli E, Ford JM.: Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin. Cancer Res 2010 Aug 26 [Epub ahead of print].
19. • O' Shaughnessy J, Osborne C, Pippen J, et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [abstract 3]. Presented at 2009 American Society of Clinical Oncology Meeting. Orlando, FL; May 29 to June 2, 2009. This is the first report of clinical results from a phase II randomized trial with BSI-201 for treatment of sporadic triple-negative advanced breast cancer.
20. O'Shaughnessy J, Osborne C, Pippen J, et al.: Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC) [abstract 3122]. Presented at 32nd San Antonio Breast Cancer Symposium. San Antonio, TX; December 9-13, 2009.
21. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 1:CAS:528:DC%2BD1MXosVKrtrw%3D 10.1056/NEJMoa0900212 19553641 This is the first phase I dose escalation study of olaparib in patients with advanced refractory solid tumors with patient population enriched for BRCA1 and BRCA2 mutation carriers
22. Tutt A, Robson M, Garber JE, et al.: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer [abstract CRA501]. Presented at 2009 American Society of Clinical Oncology Meeting. Orlando, FL; May 29 to June 2, 2009.
23. Dent R, Lindeman G, Clemons M, et al.: Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first-or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial [abstract 1018]. Presented at 2010 American Society of Clinical Oncology Meeting. Chicago, IL; June 4-8, 2010.
24. AM Mendes-Pereira SA Martin R Brough, et al. 2009 Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 315 322 1:CAS:528:DC%2BD1MXhsVSltL%2FK 10.1002/emmm.200900041 20049735
25. DM Weinstock K Nakanishi HR Helgadottir M Jasin 2006 Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase Methods Enzymol 409 524 540 1:CAS:528:DC%2BD2sXmt1Ghsb4%3D 10.1016/S0076-6879(05)09031-2 16793422
26. WM Bonner CE Redon JS Dickey, et al. 2008 GammaH2AX and cancer Nat Rev Cancer 8 957 967 1:CAS:528:DC%2BD1cXhsVWhu7rK 10.1038/nrc2523 19005492
27. CA Banuelos JP Banath JY Kim, et al. 2009 gammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation Clin Cancer Res 15 3344 3353 1:CAS:528:DC%2BD1MXmtVKmurY%3D 10.1158/1078-0432.CCR-08-3114 19401347
28. H Willers AG Taghian CM Luo, et al. 2009 Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies Mol Cancer Res 7 1304 1309 1:CAS:528:DC%2BD1MXhtVWrsL%2FK 10.1158/1541-7786.MCR-09-0149 19671671
29. Y Li PH Brown 2007 Translational approaches for the prevention of estrogen receptor-negative breast cancer Eur J Cancer Prev 16 203 215 1:CAS:528:DC%2BD2sXlvF2ltbc%3D 10.1097/CEJ.0b013e328011ed98 17415091 (Pubitemid 46597424)
30. VG Vogel JP Costantino DL Wickerham, et al. 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2727 2741 1:CAS:528:DC%2BD28XmtFOltLc%3D 10.1001/jama.295.23.joc60074 16754727
31. B Fisher JP Costantino DL Wickerham, et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1371 1388 1:CAS:528:DyaK1cXmtlelurs%3D 10.1093/jnci/90.18.1371 9747868
32. KA Metcalfe D Birenbaum-Carmeli J Lubinski, et al. 2008 International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers Int J Cancer 122 2017 2022 1:CAS:528:DC%2BD1cXkt1ChsL8%3D 10.1002/ijc.23340 18196574 (Pubitemid 351441190)
33. J Jonkers A Berns 2002 Conditional mouse models of sporadic cancer Nat Rev Cancer 2 251 265 1:CAS:528:DC%2BD38XivFGqt70%3D 10.1038/nrc777 12001987
34. AS Whittemore G Gong EM John, et al. 2004 Prevalence of BRCA1 mutation carriers among U.S. non-Hispanic Whites Cancer Epidemiol Biomarkers Prev 13 2078 2083 1:CAS:528:DC%2BD2cXhtVOjsLvF 15598764
35. EM John A Miron G Gong, et al. 2007 Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups JAMA 298 2869 2876 1:CAS:528:DC%2BD1cXmvFOr 10.1001/jama.298.24.2869 18159056
36. AW Kurian LA McClure EM John, et al. 2009 Second primary breast cancer occurrence according to hormone receptor status J Natl Cancer Inst 101 1058 1065 1:CAS:528:DC%2BD1MXpvF2qur4%3D 10.1093/jnci/djp181 19590058